Advertisement
Canadian Journal of Cardiology

The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation

Published:October 22, 2020DOI:https://doi.org/10.1016/j.cjca.2020.09.001

      Abstract

      The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines program was developed to aid clinicians in the management of these complex patients, as well as to provide direction to policy makers and health care systems regarding related issues. The most recent comprehensive CCS AF guidelines update was published in 2010. Since then, periodic updates were published dealing with rapidly changing areas. However, since 2010 a large number of developments had accumulated in a wide range of areas, motivating the committee to complete a thorough guideline review. The 2020 iteration of the CCS AF guidelines represents a comprehensive renewal that integrates, updates, and replaces the past decade of guidelines, recommendations, and practical tips. It is intended to be used by practicing clinicians across all disciplines who care for patients with AF. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system was used to evaluate recommendation strength and the quality of evidence. Areas of focus include: AF classification and definitions, epidemiology, pathophysiology, clinical evaluation, screening and opportunistic AF detection, detection and management of modifiable risk factors, integrated approach to AF management, stroke prevention, arrhythmia management, sex differences, and AF in special populations. Extensive use is made of tables and figures to synthesize important material and present key concepts. This document should be an important aid for knowledge translation and a tool to help improve clinical management of this important and challenging arrhythmia.

      Résumé

      Le programme de lignes directrices de la Société canadienne de cardiologie (SCC) en matière de fibrillation auriculaire (FA) a été élaboré pour aider les cliniciens à prendre en charge ces patients complexes, ainsi que pour orienter les décideurs politiques et les systèmes de soins de santé sur des questions connexes. La dernière édition complète des lignes directrices de la SCC en matière de FA a été publiée en 2010. Depuis lors, des mises à jour périodiques ont été publiées, traitant de domaines en évolution rapide. Cependant, en 2020, un grand nombre de développements s'y étaient ajoutés, couvrant un large éventail de domaines, ce qui a motivé le comité à créer une refonte complète des lignes directrices. L'édition 2020 des lignes directrices de la SCC en matière de FA représente un renouvellement complet qui intègre, met à jour et remplace les lignes directrices, les recommandations et les conseils pratiques des dix dernières années. Elle est destinée à être utilisée par les cliniciens praticiens de toutes les disciplines qui s'occupent de patients souffrant de FA. L'approche GRADE (Gradation des Recommandations, de l’Appréciation, du Développement et des Évaluations) a été utilisée pour évaluer la pertinence des recommandations et la qualité des résultats. Les domaines d'intérêt incluent : la classification et les définitions de la FA, son épidémiologie, sa physiopathologie, l’évaluation clinique, le dépistage de la FA, la détection et la gestion des facteurs de risque modifiables, l’approche intégrée de la gestion de la FA, la prévention des accidents vasculaires cérébraux, la gestion de l'arythmie, les différences entre les sexes et la FA dans des populations particulières. Des tableaux et figures ont été largement utilisés pour synthétiser les éléments importants et présenter les concepts clés. Ce document devrait représenter une aide importante pour l’intégration des connaissances et un outil pour aider à améliorer la gestion clinique de cette arythmie importante et difficile à traiter.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Canadian Cardiovascular Society Consensus Conference on Atrial Fibrillation.
        Can J Cardiol. 1996; 12: 1A-61A
        • Andrade J.G.
        • Nattel S.
        • Macle L.
        The Canadian Cardiovascular Society Atrial Fibrillation Guidelines Program: a look back over the last 10 years and a look forward.
        Can J Cardiol. 2020; 36: 1839-1842
      2. 2004 Canadian Cardiovascular Society Consensus Conference: Atrial Fibrillation.
        Can J Cardiol. 2005; 21: 9B-73B
        • Cairns J.A.
        • Connolly S.
        • McMurtry S.
        • et al.
        Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
        Can J Cardiol. 2011; 27: 74-90
        • Skanes A.C.
        • Healey J.S.
        • Cairns J.A.
        • et al.
        Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
        Can J Cardiol. 2012; 28: 125-136
        • Verma A.
        • Cairns J.A.
        • Mitchell L.B.
        • et al.
        2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
        Can J Cardiol. 2014; 30: 1114-1130
        • Macle L.
        • Cairns J.
        • Leblanc K.
        • et al.
        2016 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.
        Can J Cardiol. 2016; 32: 1170-1185
        • Andrade J.G.
        • Verma A.
        • Mitchell L.B.
        • et al.
        2018 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.
        Can J Cardiol. 2018; 34: 1371-1392
        • Guyatt G.H.
        • Oxman A.D.
        • Vist G.E.
        • et al.
        GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
        BMJ. 2008; 336: 924-926
        • Andrade J.G.
        • Macle L.
        • Nattel S.
        • Verma A.
        • Cairns J.
        Contemporary atrial fibrillation management: a comparison of the current AHA/ACC/HRS, CCS, and ESC guidelines.
        Can J Cardiol. 2017; 33: 965-976
        • Charitos E.I.
        • Ziegler P.D.
        • Stierle U.
        • et al.
        Atrial fibrillation burden estimates derived from intermittent rhythm monitoring are unreliable estimates of the true atrial fibrillation burden.
        Pacing Clin Electrophysiol. 2014; 37: 1210-1218
        • Charitos E.I.
        • Purerfellner H.
        • Glotzer T.V.
        • Ziegler P.D.
        Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices.
        J Am Coll Cardiol. 2014; 63: 2840-2848
        • Andrade J.G.
        • Yao R.R.J.
        • Deyell M.W.
        • et al.
        Clinical assessment of AF pattern is poorly correlated with AF burden and post ablation outcomes: a CIRCA-DOSE sub-study.
        J Electrocardiol. 2020; 60: 159-164
        • Banerjee A.
        • Taillandier S.
        • Olesen J.B.
        • et al.
        Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project.
        Int J Cardiol. 2013; 167: 2682-2687
        • Vanassche T.
        • Lauw M.N.
        • Eikelboom J.W.
        • et al.
        Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
        Eur Heart J. 2015; 36 (281-7a)
        • Atar D.
        • Berge E.
        • Le Heuzey J.Y.
        • et al.
        The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events.
        Europace. 2020; 22: 195-204
        • Andrade J.G.
        • Deyell M.W.
        • Verma A.
        • et al.
        Association of atrial fibrillation episode duration with arrhythmia recurrence following ablation: a secondary analysis of a randomized clinical trial.
        JAMA Netw Open. 2020; 3e208748
        • Quon M.J.
        • Pilote L.
        Is secondary atrial fibrillation different? Or Is atrial fibrillation just atrial fibrillation?.
        Canadian Journal of General Internal Medicine. 2018; 13: 27-30
        • Wyse D.G.
        • Van Gelder I.C.
        • Ellinor P.T.
        • et al.
        Lone atrial fibrillation: does it exist?.
        J Am Coll Cardiol. 2014; 63: 1715-1723
        • Cheung C.C.
        • Andrade J.G.
        Reversible or provoked atrial fibrillation?: The devil in the details.
        JACC Clin Electrophysiol. 2018; 4: 563-564
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Connolly S.J.
        • Eikelboom J.
        • Joyner C.
        • et al.
        Apixaban in patients with atrial fibrillation.
        N Engl J Med. 2011; 364: 806-817
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Macle L.
        • Cairns J.A.
        • Andrade J.G.
        • et al.
        The 2014 atrial fibrillation guidelines companion: a practical approach to the use of the Canadian Cardiovascular Society guidelines.
        Can J Cardiol. 2015; 31: 1207-1218
        • Noseworthy P.A.
        • Yao X.
        • Shah N.D.
        • Gersh B.J.
        Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease.
        Int J Cardiol. 2016; 209: 181-183
        • Siontis K.C.
        • Yao X.
        • Gersh B.J.
        • Noseworthy P.A.
        Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis.
        Circulation. 2017; 135: 714-716
        • Andrade J.
        • Khairy P.
        • Dobrev D.
        • Nattel S.
        The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms.
        Circ Res. 2014; 114: 1453-1468
        • Kannel W.B.
        • Wolf P.A.
        • Benjamin E.J.
        • Levy D.
        Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.
        Am J Cardiol. 1998; 82: 2N-9N
        • Piccini J.P.
        • Hammill B.G.
        • Sinner M.F.
        • et al.
        Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007.
        Circ Cardiovasc Qual Outcomes. 2012; 5: 85-93
        • Kannel W.B.
        • Abbott R.D.
        • Savage D.D.
        • McNamara P.M.
        Epidemiologic features of chronic atrial fibrillation: the Framingham study.
        N Engl J Med. 1982; 306: 1018-1022
        • Furberg C.D.
        • Psaty B.M.
        • Manolio T.A.
        • et al.
        Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).
        Am J Cardiol. 1994; 74: 236-241
        • Rietbrock S.
        • Heeley E.
        • Plumb J.
        • van Staa T.
        Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme.
        Am Heart J. 2008; 156: 57-64
        • Chiang C.E.
        • Naditch-Brule L.
        • Murin J.
        • et al.
        Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry.
        Circ Arrhythm Electrophysiol. 2012; 5: 632-639
        • Go A.S.
        • Hylek E.M.
        • Phillips K.A.
        • et al.
        Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
        JAMA. 2001; 285: 2370-2375
        • Miyasaka Y.
        • Barnes M.E.
        • Gersh B.J.
        • et al.
        Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.
        Circulation. 2006; 114: 119-125
        • Dorian P.
        • Jung W.
        • Newman D.
        • et al.
        The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy.
        J Am Coll Cardiol. 2000; 36: 1303-1309
        • Savelieva I.
        • Paquette M.
        • Dorian P.
        • Luderitz B.
        • Camm A.J.
        Quality of life in patients with silent atrial fibrillation.
        Heart. 2001; 85: 216-217
        • Singh S.N.
        • Tang X.C.
        • Singh B.N.
        • et al.
        Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program substudy.
        J Am Coll Cardiol. 2006; 48: 721-730
        • Thrall G.
        • Lane D.
        • Carroll D.
        • Lip G.Y.
        Quality of life in patients with atrial fibrillation: a systematic review.
        Am J Med. 2006; 119 (448.e1-19)
        • Kang Y.
        Relation of atrial arrhythmia-related symptoms to health-related quality of life in patients with newly diagnosed atrial fibrillation: a community hospital-based cohort.
        Heart Lung. 2006; 35: 170-177
        • Wolf P.A.
        • Mitchell J.B.
        • Baker C.S.
        • Kannel W.B.
        • D’Agostino R.B.
        Impact of atrial fibrillation on mortality, stroke, and medical costs.
        Arch Intern Med. 1998; 158: 229-234
        • Andersson T.
        • Magnuson A.
        • Bryngelsson I.L.
        • et al.
        All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study.
        Eur Heart J. 2013; 34: 1061-1067
        • Benjamin E.J.
        • Virani S.S.
        • Callaway C.W.
        • et al.
        Heart disease and stroke statistics-2018 update: a report from the American Heart Association.
        Circulation. 2018; 137: e67-e492
        • Lee E.
        • Choi E.K.
        • Han K.D.
        • et al.
        Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study.
        PLoS One. 2018; 13e0209687
        • Petty G.W.
        • Brown Jr., R.D.
        • Whisnant J.P.
        • et al.
        Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence.
        Stroke. 2000; 31: 1062-1068
        • Bruggenjurgen B.
        • Rossnagel K.
        • Roll S.
        • et al.
        The impact of atrial fibrillation on the cost of stroke: the Berlin Acute Stroke study.
        Value Health. 2007; 10: 137-143
        • Gladstone D.J.
        • Bui E.
        • Fang J.
        • et al.
        Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated.
        Stroke. 2009; 40: 235-240
        • Healey J.S.
        • Connolly S.J.
        • Gold M.R.
        • et al.
        Subclinical atrial fibrillation and the risk of stroke.
        N Engl J Med. 2012; 366: 120-129
        • Hart R.G.
        • Pearce L.A.
        • Aguilar M.I.
        Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
        Ann Intern Med. 2007; 146: 857-867
        • Ruff C.T.
        • Giugliano R.P.
        • Braunwald E.
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
        Lancet. 2014; 383: 955-962
        • Stewart S.
        • Murphy N.F.
        • Walker A.
        • McGuire A.
        • McMurray J.J.
        Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK.
        Heart. 2004; 90: 286-292
        • Humphries K.H.
        • Jackevicius C.
        • Gong Y.
        • et al.
        Population rates of hospitalization for atrial fibrillation/flutter in Canada.
        Can J Cardiol. 2004; 20: 869-876
        • Wu E.Q.
        • Birnbaum H.G.
        • Mareva M.
        • et al.
        Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
        Curr Med Res Opin. 2005; 21: 1693-1699
        • Lee W.C.
        • Lamas G.A.
        • Balu S.
        • et al.
        Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective.
        J Med Econ. 2008; 11: 281-298
        • Kim M.H.
        • Lin J.
        • Hussein M.
        • Kreilick C.
        • Battleman D.
        Cost of atrial fibrillation in United States managed care organizations.
        Adv Ther. 2009; 26: 847-857
        • O’Reilly D.J.
        • Hopkins R.B.
        • Healey J.S.
        • et al.
        The burden of atrial fibrillation on the hospital sector in Canada.
        Can J Cardiol. 2013; 29: 229-235
        • Meyre P.
        • Blum S.
        • Berger S.
        • et al.
        Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta-analysis.
        Can J Cardiol. 2019; 35: 1332-1343
        • Nattel S.
        New ideas about atrial fibrillation 50 years on.
        Nature. 2002; 415: 219-226
        • Voigt N.
        • Heijman J.
        • Wang Q.
        • et al.
        Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation.
        Circulation. 2014; 129: 145-156
        • Voigt N.
        • Li N.
        • Wang Q.
        • et al.
        Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation.
        Circulation. 2012; 125: 2059-2070
        • Yao C.
        • Veleva T.
        • Scott Jr., L.
        • et al.
        Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation.
        Circulation. 2018; 138: 2227-2242
        • Nishida K.
        • Datino T.
        • Macle L.
        • Nattel S.
        Atrial fibrillation ablation: translating basic mechanistic insights to the patient.
        J Am Coll Cardiol. 2014; 64: 823-831
        • Pathak R.K.
        • Middeldorp M.E.
        • Lau D.H.
        • et al.
        Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study.
        J Am Coll Cardiol. 2014; 64: 2222-2231
        • Lau D.H.
        • Nattel S.
        • Kalman J.M.
        • Sanders P.
        Modifiable risk factors and atrial fibrillation.
        Circulation. 2017; 136: 583-596
        • Dorian P.
        • Guerra P.G.
        • Kerr C.R.
        • et al.
        Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale.
        Circ Arrhythm Electrophysiol. 2009; 2: 218-224
        • Haissaguerre M.
        • Fischer B.
        • Labbe T.
        • et al.
        Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways.
        Am J Cardiol. 1992; 69: 493-497
        • Brembilla-Perrot B.
        • Olivier A.
        • Villemin T.
        • et al.
        Prediction of atrial fibrillation in patients with supraventricular tachyarrhythmias treated with catheter ablation or not. Classical scores are not useful.
        Int J Cardiol. 2016; 220: 102-106
        • Wolf P.A.
        • Dawber T.R.
        • Thomas Jr., H.E.
        • Kannel W.B.
        Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.
        Neurology. 1978; 28: 973-977
        • Kim D.D.
        • Young S.
        • Cutfield R.
        A survey of thyroid function test abnormalities in patients presenting with atrial fibrillation and flutter to a New Zealand district hospital.
        N Z Med J. 2008; 121: 82-86
        • Gladstone D.J.
        • Spring M.
        • Dorian P.
        • et al.
        Atrial fibrillation in patients with cryptogenic stroke.
        N Engl J Med. 2014; 370: 2467-2477
        • Sanna T.
        • Diener H.C.
        • Passman R.S.
        • et al.
        Cryptogenic stroke and underlying atrial fibrillation.
        N Engl J Med. 2014; 370: 2478-2486
        • Hindricks G.
        • Piorkowski C.
        • Tanner H.
        • et al.
        Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence.
        Circulation. 2005; 112: 307-313
        • Verma A.
        • Champagne J.
        • Sapp J.
        • et al.
        Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study.
        JAMA Intern Med. 2013; 173: 149-156
        • Walters T.E.
        • Wick K.
        • Tan G.
        • et al.
        Psychological distress and suicidal ideation in patients with atrial fibrillation: prevalence and response to management strategy.
        J Am Heart Assoc. 2018; 7e005502
        • Dorian P.
        • Cvitkovic S.S.
        • Kerr C.R.
        • et al.
        A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: the CCS-SAF scale.
        Can J Cardiol. 2006; 22: 383-386
        • Reynolds M.R.
        • Ellis E.
        • Zimetbaum P.
        Quality of life in atrial fibrillation: measurement tools and impact of interventions.
        J Cardiovasc Electrophysiol. 2008; 19: 762-768
        • Miyazaki M.
        • Nakashima A.
        • Nakamura Y.
        • et al.
        Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: an observational cross-sectional pilot study.
        PLoS One. 2018; 13e0204814
        • Miura K.
        • Ikemura N.
        • Kimura T.
        • et al.
        Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation.
        Am Heart J. 2020; 222: 83-92
        • Mairesse G.H.
        • Moran P.
        • Van Gelder I.C.
        • et al.
        Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE).
        Europace. 2017; 19: 1589-1623
        • Lowres N.
        • Olivier J.
        • Chao T.F.
        • et al.
        Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals.
        PLoS Med. 2019; 16e1002903
        • Morgan S.
        • Mant D.
        Randomised trial of two approaches to screening for atrial fibrillation in UK general practice.
        Br J Gen Pract. 2002; 52: 377-380
        • Hobbs F.D.
        • Fitzmaurice D.A.
        • Mant J.
        • et al.
        A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.
        Health Technol Assess. 2005; 9 (iii-iv, ix-x, 1-74)
        • Svennberg E.
        • Engdahl J.
        • Al-Khalili F.
        • et al.
        Mass screening for untreated atrial fibrillation: the STROKESTOP study.
        Circulation. 2015; 131: 2176-2184
        • Kaasenbrood F.
        • Hollander M.
        • Rutten F.H.
        • et al.
        Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination.
        Europace. 2016; 18: 1514-1520
        • Lowres N.
        • Neubeck L.
        • Salkeld G.
        • et al.
        Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study.
        Thromb Haemost. 2014; 111: 1167-1176
        • Sandhu R.K.
        • Dolovich L.
        • Deif B.
        • et al.
        High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme.
        Open Heart. 2016; 3e000515
        • Freedman B.
        • Camm J.
        • Calkins H.
        • et al.
        Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration.
        Circulation. 2017; 135: 1851-1867
        • Moran P.S.
        • Teljeur C.
        • Ryan M.
        • Smith S.M.
        Systematic screening for the detection of atrial fibrillation.
        Cochrane Database Syst Rev. 2016; 6: CD009586
        • Tarride J.E.
        • Dolovich L.
        • Blackhouse G.
        • et al.
        Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation.
        CMAJ Open. 2017; 5: E653-E661
        • Tarride J.E.
        • Quinn F.R.
        • Blackhouse G.
        • et al.
        Is screening for atrial fibrillation in Canadian family practices cost-effective in patients 65 years and older?.
        Can J Cardiol. 2018; 34: 1522-1525
        • Andrade J.G.
        • Godin R.
        • Nault I.
        Large-scale implementation of a pragmatic atrial fibrillation screening program in Canadian community practice.
        Pacing Clin Electrophysiol. 2020; 43: 768-769
        • Perez M.V.
        • Mahaffey K.W.
        • Hedlin H.
        • et al.
        Large-scale assessment of a Smartwatch to identify atrial fibrillation.
        N Engl J Med. 2019; 381: 1909-1917
        • Daoud E.G.
        • Glotzer T.V.
        • Wyse D.G.
        • et al.
        Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli on the basis of stored device data: a subgroup analysis of TRENDS.
        Heart Rhythm. 2011; 8: 1416-1423
        • Van Gelder I.C.
        • Healey J.S.
        • Crijns H.
        • et al.
        Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
        Eur Heart J. 2017; 38: 1339-1344
        • Swiryn S.
        • Orlov M.V.
        • Benditt D.G.
        • et al.
        Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes.
        Circulation. 2016; 134: 1130-1140
        • Gorenek B.C.
        • Bax J.
        • Boriani G.
        • et al.
        Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE).
        Europace. 2017; 19: 1556-1578
        • Glotzer T.V.
        • Hellkamp A.S.
        • Zimmerman J.
        • et al.
        Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST).
        Circulation. 2003; 107: 1614-1619
        • Glotzer T.V.
        • Daoud E.G.
        • Wyse D.G.
        • et al.
        The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.
        Circ Arrhythm Electrophysiol. 2009; 2: 474-480
        • Capucci A.
        • Santini M.
        • Padeletti L.
        • et al.
        Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers.
        J Am Coll Cardiol. 2005; 46: 1913-1920
        • Marini C.
        • De Santis F.
        • Sacco S.
        • et al.
        Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study.
        Stroke. 2005; 36: 1115-1119
        • Cotter P.E.
        • Martin P.J.
        • Ring L.
        • et al.
        Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke.
        Neurology. 2013; 80: 1546-1550
        • Hart R.G.
        • Diener H.C.
        • Coutts S.B.
        • et al.
        Embolic strokes of undetermined source: the case for a new clinical construct.
        Lancet Neurol. 2014; 13: 429-438
        • Johnston S.C.
        • Easton J.D.
        • Farrant M.
        • et al.
        Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.
        N Engl J Med. 2018; 379: 215-225
        • Hart R.G.
        • Sharma M.
        • Mundl H.
        • et al.
        Rivaroxaban for stroke prevention after embolic stroke of undetermined source.
        N Engl J Med. 2018; 378: 2191-2201
        • Investigators AWGotA
        • Connolly S.
        • Pogue J.
        • et al.
        Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
        Lancet. 2006; 367: 1903-1912
        • Ntaios G.
        • Papavasileiou V.
        • Diener H.C.
        • Makaritsis K.
        • Michel P.
        Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials.
        Stroke. 2012; 43: 3298-3304
        • Andrade J.G.
        • Field T.
        • Khairy P.
        Detection of occult atrial fibrillation in patients with embolic stroke of uncertain source: a work in progress.
        Front Physiol. 2015; 6: 100
        • Sposato L.A.
        • Cipriano L.E.
        • Saposnik G.
        • et al.
        Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis.
        Lancet Neurol. 2015; 14: 377-387
        • Kishore A.
        • Vail A.
        • Majid A.
        • et al.
        Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis.
        Stroke. 2014; 45: 520-526
        • Higgins P.
        • MacFarlane P.W.
        • Dawson J.
        • et al.
        Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial.
        Stroke. 2013; 44: 2525-2531
        • Brachmann J.
        • Morillo C.A.
        • Sanna T.
        • et al.
        Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the Cryptogenic Stroke and Underlying Atrial Fibrillation trial.
        Circ Arrhythm Electrophysiol. 2016; 9e003333
        • Tsivgoulis G.
        • Katsanos A.H.
        • Kohrmann M.
        • et al.
        Duration of implantable cardiac monitoring and detection of atrial fibrillation in ischemic stroke patients: a systematic review and meta-analysis.
        J Stroke. 2019; 21: 302-311
        • Yang X.M.
        • Rao Z.Z.
        • Gu H.Q.
        • et al.
        Atrial fibrillation known before or detected after stroke share similar risk of ischemic stroke recurrence and death.
        Stroke. 2019; 50: 1124-1129
        • Yong J.H.
        • Thavorn K.
        • Hoch J.S.
        • et al.
        Potential cost-effectiveness of ambulatory cardiac rhythm monitoring after cryptogenic stroke.
        Stroke. 2016; 47: 2380-2385
        • Diamantopoulos A.
        • Sawyer L.M.
        • Lip G.Y.
        • et al.
        Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke.
        Int J Stroke. 2016; 11: 302-312
        • Wein T.
        • Lindsay M.P.
        • Cote R.
        • et al.
        Canadian stroke best practice recommendations: secondary prevention of stroke, sixth edition practice guidelines, update 2017.
        Int J Stroke. 2018; 13: 420-443
        • Mitchell G.F.
        • Vasan R.S.
        • Keyes M.J.
        • et al.
        Pulse pressure and risk of new-onset atrial fibrillation.
        JAMA. 2007; 297: 709-715
        • Dublin S.
        • French B.
        • Glazer N.L.
        • et al.
        Risk of new-onset atrial fibrillation in relation to body mass index.
        Arch Intern Med. 2006; 166: 2322-2328
        • Rosengren A.
        • Hauptman P.J.
        • Lappas G.
        • et al.
        Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men.
        Eur Heart J. 2009; 30: 1113-1120
        • Schnabel R.B.
        • Sullivan L.M.
        • Levy D.
        • et al.
        Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.
        Lancet. 2009; 373: 739-745
        • Alonso A.
        • Krijthe B.P.
        • Aspelund T.
        • et al.
        Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium.
        J Am Heart Assoc. 2013; 2e000102
        • Attia Z.I.
        • Noseworthy P.A.
        • Lopez-Jimenez F.
        • et al.
        An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction.
        Lancet. 2019; 394: 861-867
        • Fein A.S.
        • Shvilkin A.
        • Shah D.
        • et al.
        Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation.
        J Am Coll Cardiol. 2013; 62: 300-305
        • Li L.
        • Wang Z.W.
        • Li J.
        • et al.
        Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies.
        Europace. 2014; 16: 1309-1314
        • Shukla A.
        • Aizer A.
        • Holmes D.
        • et al.
        Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis.
        JACC: Clin Electrophysiol. 2015; 1: 41-51
        • Abed H.S.
        • Wittert G.A.
        • Leong D.P.
        • et al.
        Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.
        JAMA. 2013; 310: 2050-2060
        • Pathak R.K.
        • Middeldorp M.E.
        • Meredith M.
        • et al.
        Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY).
        J Am Coll Cardiol. 2015; 65: 2159-2169
        • Mahajan R.
        • Lau D.H.
        • Brooks A.G.
        • et al.
        Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity.
        J Am Coll Cardiol. 2015; 66: 1-11
        • Pathak R.K.
        • Elliott A.
        • Middeldorp M.E.
        • et al.
        Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study.
        J Am Coll Cardiol. 2015; 66: 985-996
        • Rienstra M.
        • Hobbelt A.H.
        • Alings M.
        • et al.
        Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
        Eur Heart J. 2018; 39: 2987-2996
        • Ogilvie I.M.
        • Newton N.
        • Welner S.A.
        • Cowell W.
        • Lip G.Y.
        Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
        Am J Med. 2010; 123: 638-645
        • Boodhoo L.
        • Bordoli G.
        • Mitchell A.R.
        • et al.
        The safety and effectiveness of a nurse led cardioversion service under sedation.
        Heart. 2004; 90: 1443-1446
        • Cruz J.
        • Mariano Z.
        • Dorian P.
        Atrial fibrillation clinics in Canada: a nationwide project report.
        Can J Cardiol. 2018; 34: 1219-1224
        • Gillis A.M.
        • Burland L.
        • Arnburg B.
        • et al.
        Treating the right patient at the right time: an innovative approach to the management of atrial fibrillation.
        Can J Cardiol. 2008; 24: 195-198
        • Elmouchi D.A.
        • VanOosterhout S.
        • Muthusamy P.
        • et al.
        Impact of an emergency department-initiated clinical protocol for the evaluation and treatment of atrial fibrillation.
        Crit Pathw Cardiol. 2014; 13: 43-48
        • Angaran P.
        • Mariano Z.
        • Dragan V.
        • et al.
        The Atrial Fibrillation Therapies after ER visit: outpatient care for patients with acute AF - the AFTER3 study.
        J Atr Fibrillation. 2015; 7: 1187
        • Carter L.
        • Gardner M.
        • Magee K.
        • et al.
        An integrated management approach to atrial fibrillation.
        J Am Heart Assoc. 2016; 5e00295
        • Hendriks J.M.
        • de W.R.
        • Crijns H.J.
        • et al.
        Nurse-led care vs usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs routine clinical care in ambulatory patients with atrial fibrillation.
        Eur Heart J. 2012; 33: 2692-2699
        • Hendriks J.
        • Tomini F.
        • van Asselt T.
        • Crijns H.
        • Vrijhoef H.
        Cost-effectiveness of a specialized atrial fibrillation clinic vs usual care in patients with atrial fibrillation.
        Europace. 2013; 15: 1128-1135
        • Wijtvliet E.
        • Tieleman R.G.
        • van Gelder I.C.
        • et al.
        Nurse-led vs usual-care for atrial fibrillation.
        Eur Heart J. 2020; 41: 634-641
        • Grady P.A.
        • Gough L.L.
        Self-management: a comprehensive approach to management of chronic conditions.
        Am J Public Health. 2014; 104: e25-e31
        • Holman H.
        • Lorig K.
        Patients as partners in managing chronic disease. Partnership is a prerequisite for effective and efficient health care.
        BMJ. 2000; 320: 526-527
        • Andrade J.G.
        • Krahn A.D.
        • Skanes A.C.
        • et al.
        Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention.
        Can J Cardiol. 2016; 32: 747-753
        • Lane D.A.
        • Ponsford J.
        • Shelley A.
        • Sirpal A.
        • Lip G.Y.
        Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project.
        Int J Cardiol. 2006; 110: 354-358
        • Hernandez Madrid A.
        • Potpara T.S.
        • Dagres N.
        • et al.
        Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association.
        Europace. 2016; 18: 463-467
        • Clifford S.
        • Barber N.
        • Horne R.
        Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework.
        J Psychosom Res. 2008; 64: 41-46
        • Wofford J.L.
        • Wells M.D.
        • Singh S.
        Best strategies for patient education about anticoagulation with warfarin: a systematic review.
        BMC Health Serv Res. 2008; 8: 40
        • Meichenbaum D.
        • Turk D.C.
        Facilitating Treatment Adherence: A Practitioner’s Guidebook.
        Plenum Press, New York1987
        • Ho P.M.
        • Magid D.J.
        • Shetterly S.M.
        • et al.
        Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease.
        Am Heart J. 2008; 155: 772-779
        • Ruppar T.M.
        • Cooper P.S.
        • Mehr D.R.
        • Delgado J.M.
        • Dunbar-Jacob J.M.
        Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials.
        J Am Heart Assoc. 2016; 5e002606
        • Kakkar A.K.
        • Mueller I.
        • Bassand J.P.
        • et al.
        Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.
        PLoS One. 2013; 8e63479
        • Camm A.J.
        • Accetta G.
        • Ambrosio G.
        • et al.
        Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.
        Heart. 2017; 103: 307-314
        • Huisman M.V.
        • Rothman K.J.
        • Paquette M.
        • et al.
        The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2.
        J Am Coll Cardiol. 2017; 69: 777-785
        • Shore S.
        • Carey E.P.
        • Turakhia M.P.
        • et al.
        Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
        Am Heart J. 2014; 167: 810-817
        • Alberts M.J.
        • Peacock W.F.
        • Fields L.E.
        • et al.
        Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke.
        Int J Cardiol. 2016; 215: 11-13
        • Gomes T.
        • Mamdani M.M.
        • Holbrook A.M.
        • Paterson J.M.
        • Juurlink D.N.
        Persistence with therapy among patients treated with warfarin for atrial fibrillation.
        Arch Intern Med. 2012; 172: 1687-1689
        • Beyer-Westendorf J.
        • Ehlken B.
        • Evers T.
        Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
        Europace. 2016; 18: 1150-1157
        • Lip G.Y.H.
        • Pan X.
        • Kamble S.
        • et al.
        Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: apixaban, warfarin, dabigatran, or rivaroxaban.
        PLoS One. 2018; 13e0195950
        • Ruigomez A.
        • Vora P.
        • Balabanova Y.
        • et al.
        Discontinuation of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK.
        BMJ Open. 2019; 9e031342
        • Yao X.
        • Abraham N.S.
        • Alexander G.C.
        • et al.
        Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation.
        J Am Heart Assoc. 2016; 5e003074
        • Ho P.M.
        • Bryson C.L.
        • Rumsfeld J.S.
        Medication adherence: its importance in cardiovascular outcomes.
        Circulation. 2009; 119: 3028-3035
        • Murray M.D.
        • Young J.
        • Hoke S.
        • et al.
        Pharmacist intervention to improve medication adherence in heart failure: a randomized trial.
        Ann Intern Med. 2007; 146: 714-725
        • Vinereanu D.
        • Lopes R.D.
        • Bahit M.C.
        • et al.
        A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial.
        Lancet. 2017; 390: 1737-1746
        • Pandya E.
        • Bajorek B.V.
        Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
        J Clin Pharm Ther. 2016; 41: 667-676
        • Giebel G.D.
        • Gissel C.
        Accuracy of mHealth devices for atrial fibrillation screening: systematic review.
        JMIR Mhealth Uhealth. 2019; 7e13641
        • Linz D.
        • Pluymaekers N.
        • Hendriks J.M.
        TeleCheck-AF for COVID-19.
        Eur Heart J. 2020; 41: 1954-1955
      3. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
        Arch Intern Med. 1994; 154: 1449-1457
      4. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators.
        Ann Intern Med. 1992; 116: 1-5
        • Olesen J.B.
        • Torp-Pedersen C.
        • Hansen M.L.
        • Lip G.Y.
        The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
        Thromb Haemost. 2012; 107: 1172-1179
        • Gage B.F.
        • Waterman A.D.
        • Shannon W.
        • et al.
        Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
        JAMA. 2001; 285: 2864-2870
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Olesen J.B.
        • Lip G.Y.
        • Hansen M.L.
        • et al.
        Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.
        BMJ. 2011; 342: d124
        • Verma A.
        • Cairns J.A.
        • Mitchell L.B.
        • et al.
        2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation.
        Can J Cardiol. 2014; 30: 1114-1130
        • Bell A.D.
        • Roussin A.
        • Cartier R.
        • et al.
        The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines.
        Can J Cardiol. 2011; 27: S1-S59
        • Proietti M.
        • Lane D.A.
        • Boriani G.
        • Lip G.Y.H.
        Stroke prevention, evaluation of bleeding risk, and anticoagulant treatment management in atrial fibrillation contemporary international guidelines.
        Can J Cardiol. 2019; 35: 619-633
        • Quinn G.R.
        • Severdija O.N.
        • Chang Y.
        • Singer D.E.
        Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation.
        Circulation. 2017; 135: 208-219
        • Chao T.F.
        • Wang K.L.
        • Liu C.J.
        • et al.
        Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan.
        J Am Coll Cardiol. 2015; 66: 1339-1347
        • Friberg L.
        • Skeppholm M.
        • Terent A.
        Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1.
        J Am Coll Cardiol. 2015; 65: 225-232
        • Singer D.E.
        • Chang Y.
        • Borowsky L.H.
        • et al.
        A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score.
        J Am Heart Assoc. 2013; 2e000250
        • Vadmann H.
        • Nielsen P.B.
        • Hjortshoj S.P.
        • et al.
        Atrial flutter and thromboembolic risk: a systematic review.
        Heart. 2015; 101: 1446-1455
        • Biblo L.A.
        • Yuan Z.
        • Quan K.J.
        • Mackall J.A.
        • Rimm A.A.
        Risk of stroke in patients with atrial flutter.
        Am J Cardiol. 2001; 87: 346-349, A349
        • Corrado G.
        • Sgalambro A.
        • Mantero A.
        • et al.
        Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Societa Italiana di Ecografia Cardiovascolare) multicentre study.
        Eur Heart J. 2001; 22: 1042-1051
        • Elhendy A.
        • Gentile F.
        • Khandheria B.K.
        • et al.
        Thromboembolic complications after electrical cardioversion in patients with atrial flutter.
        Am J Med. 2001; 111: 433-438
        • Gallagher M.M.
        • Hennessy B.J.
        • Edvardsson N.
        • et al.
        Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion.
        J Am Coll Cardiol. 2002; 40: 926-933
        • Ghali W.A.
        • Wasil B.I.
        • Brant R.
        • Exner D.V.
        • Cornuz J.
        Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis.
        Am J Med. 2005; 118: 101-107
        • Al-Kawaz M.
        • Omran S.S.
        • Parikh N.S.
        • et al.
        Comparative risks of ischemic stroke in atrial flutter versus atrial fibrillation.
        J Stroke Cerebrovasc Dis. 2018; 27: 839-844
        • Gula L.J.
        • Redfearn D.P.
        • Jenkyn K.B.
        • et al.
        Elevated incidence of atrial fibrillation and stroke in patients with atrial flutter-a population-based study.
        Can J Cardiol. 2018; 34: 774-783
        • Jin M.N.
        • Song C.
        • Kim T.H.
        • et al.
        CHA(2)DS(2)-VASc score in the prediction of ischemic stroke in patients after radiofrequency catheter ablation of typical atrial flutter.
        Yonsei Med J. 2018; 59: 236-242
        • Lin Y.S.
        • Chen Y.L.
        • Chen T.H.
        • et al.
        Comparison of clinical outcomes among patients with atrial fibrillation or atrial flutter stratified by CHA2DS2-VASc score.
        JAMA Netw Open. 2018; 1e180941
        • Chen Y.L.
        • Lin Y.S.
        • Wang H.T.
        • et al.
        Clinical outcomes of solitary atrial flutter patients using anticoagulation therapy: a national cohort study.
        Europace. 2019; 21: 313-321
        • Parikh M.G.
        • Aziz Z.
        • Krishnan K.
        • Madias C.
        • Trohman R.G.
        Usefulness of transesophageal echocardiography to confirm clinical utility of CHA2DS2-VASc and CHADS2 scores in atrial flutter.
        Am J Cardiol. 2012; 109: 550-555
        • Eckman M.H.
        • Singer D.E.
        • Rosand J.
        • Greenberg S.M.
        Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation.
        Circ Cardiovasc Qual Outcomes. 2011; 4: 14-21
        • You J.J.
        • Singer D.E.
        • Howard P.A.
        • et al.
        Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141 (e531S-75S)
        • Saposnik G.
        • Gladstone D.
        • Raptis R.
        • et al.
        Atrial fibrillation in ischemic stroke: predicting response to thrombolysis and clinical outcomes.
        Stroke. 2013; 44: 99-104
        • Mant J.
        • Hobbs F.D.R.
        • Fletcher K.
        • et al.
        Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.
        Lancet. 2007; 370: 493-503
        • Andersen L.V.
        • Vestergaard P.
        • Deichgraeber P.
        • et al.
        Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis.
        Heart. 2008; 94: 1607-1613
        • Connolly S.J.
        • Pogue J.
        • Eikelboom J.
        • et al.
        ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.
        Circulation. 2008; 118: 2029-2037
        • Wan Y.
        • Heneghan C.
        • Perera R.
        • et al.
        Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.
        Circ Cardiovasc Qual Outcomes. 2008; 1: 84-91
        • Haas S.
        • Camm A.J.
        • Bassand J.P.
        • et al.
        Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.
        Am Heart J. 2019; 213: 35-46
        • Eikelboom J.W.
        • Connolly S.J.
        • Brueckmann M.
        • et al.
        Dabigatran versus warfarin in patients with mechanical heart valves.
        N Engl J Med. 2013; 369: 1206-1214
        • Adams G.F.
        • Merrett J.D.
        • Hutchinson W.M.
        • Pollock A.M.
        Cerebral embolism and mitral stenosis: survival with and without anticoagulants.
        J Neurol Neurosurg Psychiatry. 1974; 37: 378-383
        • Rush C.J.
        • Campbell R.T.
        • Jhund P.S.
        • Petrie M.C.
        • McMurray J.J.V.
        Association is not causation: treatment effects cannot be estimated from observational data in heart failure.
        Eur Heart J. 2018; 39: 3417-3438
        • Bell A.D.
        • Gross P.
        • Heffernan M.
        • et al.
        Appropriate use of antithrombotic medication in Canadian patients with nonvalvular atrial fibrillation.
        Am J Cardiol. 2016; 117: 1107-1111
        • Steinberg B.A.
        • Shrader P.
        • Thomas L.
        • et al.
        Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry.
        J Am Coll Cardiol. 2016; 68: 2597-2604
        • Yao X.
        • Shah N.D.
        • Sangaralingham L.R.
        • Gersh B.J.
        • Noseworthy P.A.
        Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.
        J Am Coll Cardiol. 2017; 69: 2779-2790
        • Olesen J.B.
        • Lip G.Y.
        • Kamper A.L.
        • et al.
        Stroke and bleeding in atrial fibrillation with chronic kidney disease.
        N Engl J Med. 2012; 367: 625-635
        • Bonde A.N.
        • Lip G.Y.
        • Kamper A.L.
        • et al.
        Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
        J Am Coll Cardiol. 2014; 64: 2471-2482
        • Nielsen P.B.
        • Lane D.A.
        • Rasmussen L.H.
        • Lip G.Y.
        • Larsen T.B.
        Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
        Clin Res Cardiol. 2015; 104: 418-429
        • Stanton B.E.
        • Barasch N.S.
        • Tellor K.B.
        Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment.
        Pharmacotherapy. 2017; 37: 412-419
        • Shah M.
        • Avgil Tsadok M.
        • Jackevicius C.A.
        • et al.
        Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.
        Circulation. 2014; 129: 1196-1203
        • Garg L.
        • Chen C.
        • Haines D.E.
        Atrial fibrillation and chronic kidney disease requiring hemodialysis - does warfarin therapy improve the risks of this lethal combination?.
        Int J Cardiol. 2016; 222: 47-50
        • Randhawa M.S.
        • Vishwanath R.
        • Rai M.P.
        • et al.
        Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis.
        JAMA Netw Open. 2020; 3e202175
        • Pokorney S.D.
        • Black-Maier E.
        • Hellkamp A.S.
        • et al.
        Oral anticoagulation and cardiovascular outcomes in patients with atrial fibrillation and end-stage renal disease.
        J Am Coll Cardiol. 2020; 75: 1299-1308
        • Del-Carpio Munoz F.
        • Gharacholou S.M.
        • Munger T.M.
        • et al.
        Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation.
        Am J Cardiol. 2016; 117: 69-75
        • Yao X.
        • Tangri N.
        • Gersh B.J.
        • et al.
        Renal outcomes in anticoagulated patients with atrial fibrillation.
        J Am Coll Cardiol. 2017; 70: 2621-2632
        • Stanifer J.W.
        • Pokorney S.D.
        • Chertow G.M.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease.
        Circulation. 2020; 141: 1384-1392
        • Chan K.E.
        • Edelman E.R.
        • Wenger J.B.
        • Thadhani R.I.
        • Maddux F.W.
        Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
        Circulation. 2015; 131: 972-979
        • Chokesuwattanaskul R.
        • Thongprayoon C.
        • Tanawuttiwat T.
        • et al.
        Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis.
        Pacing Clin Electrophysiol. 2018; 41: 627-634
        • Reed D.
        • Palkimas S.
        • Hockman R.
        • et al.
        Safety and effectiveness of apixaban compared to warfarin in dialysis patients.
        Res Pract Thromb Haemost. 2018; 2: 291-298
        • Siontis K.C.
        • Zhang X.
        • Eckard A.
        • et al.
        Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States.
        Circulation. 2018; 138: 1519-1529
        • Gong I.Y.
        • Kim R.B.
        Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
        Can J Cardiol. 2013; 29: S24-S33
        • Fox K.A.
        • Piccini J.P.
        • Wojdyla D.
        • et al.
        Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
        Eur Heart J. 2011; 32: 2387-2394
        • Bohula E.A.
        • Giugliano R.P.
        • Ruff C.T.
        • et al.
        Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial.
        Circulation. 2016; 134: 24-36
        • Andrade J.G.
        • Hawkins N.M.
        • Fordyce C.B.
        • et al.
        Variability in non-vitamin K antagonist oral anticoagulants dose adjustment in atrial fibrillation patients with renal dysfunction: the Influence of Renal Function Estimation Formulae.
        Can J Cardiol. 2018; 34: 1010-1018
        • Kralev S.
        • Schneider K.
        • Lang S.
        • Suselbeck T.
        • Borggrefe M.
        Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography.
        PLoS One. 2011; 6e24964
        • Lip G.Y.
        • Laroche C.
        • Dan G.A.
        • et al.
        A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.
        Europace. 2014; 16: 308-319
        • Connolly S.
        • Pogue J.
        • Hart R.
        • et al.
        Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
        Lancet. 2006; 367: 1903-1912
        • Baigent C.
        • Blackwell L.
        • et al.
        • Antithrombotic Trialists’ (ATT) Collaboration
        Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
        Lancet. 2009; 373: 1849-1860
        • Anand S.S.
        • Yusuf S.
        Oral anticoagulants in patients with coronary artery disease.
        J Am Coll Cardiol. 2003; 41 (62S-9S)
        • Eikelboom J.W.
        • Connolly S.J.
        • Bosch J.
        • et al.
        Rivaroxaban with or without aspirin in stable cardiovascular disease.
        N Engl J Med. 2017; 377: 1319-1330
      5. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators.
        Lancet. 1997; 350: 389-396
        • Fiore L.D.
        • Ezekowitz M.D.
        • Brophy M.T.
        • et al.
        Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.
        Circulation. 2002; 105: 557-563
        • Brouwer M.A.
        • van den Bergh P.J.
        • Aengevaeren W.R.
        • et al.
        Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 trial.
        Circulation. 2002; 106: 659-665
        • Hurlen M.
        • Abdelnoor M.
        • Smith P.
        • Erikssen J.
        • Arnesen H.
        Warfarin, aspirin, or both after myocardial infarction.
        N Engl J Med. 2002; 347: 969-974
        • van Es R.F.
        • Jonker J.J.
        • Verheugt F.W.
        • et al.
        Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.
        Lancet. 2002; 360: 109-113
        • Herlitz J.
        • Holm J.
        • Peterson M.
        • et al.
        Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA study.
        Eur Heart J. 2004; 25: 232-239
        • Yasuda S.
        • Kaikita K.
        • Ogawa H.
        • et al.
        Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): protocol for a multicenter, prospective, randomized, open-label, parallel group study.
        Int J Cardiol. 2018; 265: 108-112
        • Mehta S.R.
        • Bainey K.R.
        • Cantor W.J.
        • et al.
        2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy.
        Can J Cardiol. 2018; 34: 214-233
        • Angiolillo D.J.
        • Goodman S.G.
        • Bhatt D.L.
        • et al.
        Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 update.
        Circ Cardiovasc Interv. 2016; 9e004395
        • Windecker S.
        • Lopes R.D.
        • Massaro T.
        • et al.
        Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial.
        Circulation. 2019; 140: 1921-1932
        • Dewilde W.J.
        • Oirbans T.
        • Verheugt F.W.
        • et al.
        Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
        Lancet. 2013; 381: 1107-1115
        • Gibson C.M.
        • Mehran R.
        • Bode C.
        • et al.
        Prevention of bleeding in patients with atrial fibrillation undergoing PCI.
        N Engl J Med. 2016; 375: 2423-2434
        • Cannon C.P.
        • Bhatt D.L.
        • Oldgren J.
        • et al.
        Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation.
        N Engl J Med. 2017; 377: 1513-1524
        • Vranckx P.
        • Valgimigli M.
        • Eckardt L.
        • et al.
        Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
        Lancet. 2019; 394: 1335-1343
        • Lopes R.D.
        • Heizer G.
        • Aronson R.
        • et al.
        Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation.
        N Engl J Med. 2019; 380: 1509-1524
        • Fiedler K.A.
        • Maeng M.
        • Mehilli J.
        • et al.
        Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial.
        J Am Coll Cardiol. 2015; 65: 1619-1629
        • Friberg L.
        • Rosenqvist M.
        • Lip G.Y.
        Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
        Eur Heart J. 2012; 33: 1500-1510
        • Choi J.
        • Kim J.
        • Shim J.H.
        • Kim M.
        • Nam G.B.
        Risks versus benefits of anticoagulation for atrial fibrillation in cirrhotic patients.
        J Cardiovasc Pharmacol. 2017; 70: 255-262
        • Khoury T.
        • Ayman A.R.
        • Cohen J.
        • et al.
        The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going.
        Digestion. 2016; 93: 149-159
        • Kuo L.
        • Chao T.F.
        • Liu C.J.
        • et al.
        Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?.
        J Am Heart Assoc. 2017; 6e005307
        • Kubitza D.
        • Roth A.
        • Becka M.
        • et al.
        Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
        Br J Clin Pharmacol. 2013; 76: 89-98
        • Mueck W.
        • Stampfuss J.
        • Kubitza D.
        • Becka M.
        Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.
        Clin Pharmacokinet. 2014; 53: 1-16
        • Lauschke V.M.
        • Ingelman-Sundberg M.
        The importance of patient-specific factors for hepatic drug response and toxicity.
        Int J Mol Sci. 2016; 17: 1714